Goyal RK, Zhang J, Davis KL, Sluga-O'Callaghan M, Kaufman PA. Early real-world treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with eribulin after prior immuno-oncology or antibody–drug conjugate therapy. Clin Breast Cancer. 2023 Nov 16;15:855-65. doi: 10.2147/BCTT.S422025
Howerton E, Dahlin K, Edholm CJ, Fox L, Reynolds M, Hollingsworth B, Lytle G, Walker M, Blackwood J, Lenhart S. The effect of governance structures on optimal control of two-patch epidemic models. J Math Biol. 2023 Oct 20;87(5):74. doi: 10.1007/s00285-023-02001-8
Mansfield C, Botha W, Vondeling GT, Klein K, Wang K, Singh J, Hackshaw MD. Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study. Breast Cancer. 2023 Jan;30(1):23-35. doi: 10.1007/s12282-022-01394-6
Brufsky A, Mitra D, Davis KL, Nagar SP, McRoy L, Cotter MJ, Stearn V. Treatment patterns and outcomes associated with palbociclib plus letrozole for postmenopausal women with HR-/HER2– advanced breast cancer enrolled in an expanded access program. Clin Breast Cancer. 2019 Oct;19(5):317-25. doi: 10.1016/j.clbc.2019.04.005